Jefferies Group LLC reissued their buy rating on shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) in a research report released on Thursday morning. Jefferies Group LLC currently has a $25.00 price objective on the stock.
A number of other research firms also recently commented on RARX. BMO Capital Markets upped their price objective on shares of Ra Pharmaceuticals from $24.00 to $31.00 and gave the company a positive rating in a research note on Tuesday, March 7th. Zacks Investment Research downgraded shares of Ra Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, March 10th. Finally, Credit Suisse Group AG reissued an outperform rating and set a $19.00 target price on shares of Ra Pharmaceuticals in a research report on Tuesday, April 18th. Five investment analysts have rated the stock with a buy rating, Ra Pharmaceuticals has an average rating of Buy and a consensus target price of $27.00.
In related news, major shareholder Bioventures Ltd Novartis sold 9,019 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $25.50, for a total transaction of $229,984.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold 120,699 shares of company stock worth $3,011,763 over the last 90 days. Institutional investors have recently made changes to their positions in the company. American International Group Inc. purchased a new position in shares of Ra Pharmaceuticals during the first quarter valued at about $102,000. Teachers Advisors LLC purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter valued at about $135,000. TIAA CREF Investment Management LLC boosted its position in shares of Ra Pharmaceuticals by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares during the period. Wells Fargo & Company MN boosted its position in shares of Ra Pharmaceuticals by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares during the period. Finally, Fred Alger Management Inc. purchased a new position in shares of Ra Pharmaceuticals during the fourth quarter valued at about $223,000. Hedge funds and other institutional investors own 2.55% of the company’s stock.
Receive News & Ratings for Ra Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com’s FREE daily email newsletter.